Guardant Reveal integrates >20,000 epigenomic signals to quantify cancer with molecular precision¹

InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.

ctDNA, circulating tumor DNA.

Important Note: Guardant Reveal was developed as Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.

1.Guardant Reveal Assay Specifications. Guardant Health, Inc; 2025.